Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical aspects of neurodegeneration. AD involves parts of the brain that control thought, language, and memory. AD is a progressive disease that begins